Form 4: Kiniksa Pharmaceuticals Directors Receive Significant Equity Grants from Baker Bros. Advisors Affiliates

Key directors affiliated with Baker Bros. Advisors LP received substantial grants of Kiniksa Pharmaceuticals Class A Ordinary Shares and Non-Qualified Share Options, aligning their interests with the company's long-term performance.

Summary

• Baker Bros. Advisors LP and its affiliated entities and individuals, including directors Felix J. Baker, Dr. Stephen R. Biggar, and M. Cantey Boyd, reported changes in their beneficial ownership of Kiniksa Pharmaceuticals International, plc (KNSA) securities.
• On June 3, 2025, a total of 8,397 Class A Ordinary Shares, in the form of Restricted Share Units (RSUs), were granted to the directors. Each director received 2,799 RSUs, which are set to vest on the earlier of June 3, 2026, or the date of the next annual shareholder meeting, contingent on continuous board service.
• Additionally, 50,394 Non-Qualified Share Options were granted on June 3, 2025, with a strike price of $29.11. Each director was granted 16,798 Share Options, which will vest in 12 equal monthly installments beginning on July 3, 2025, and are set to expire on June 2, 2035.
• These equity awards were issued under the Issuer's 2018 Incentive Award Plan, as amended.
• Julian C. Baker and Felix J. Baker are deemed to have an indirect pecuniary interest in these securities through their ownership interests in the general partners of 667, L.P. and Baker Brothers Life Sciences, L.P. (the 'Funds').
• Per the policies of Baker Bros. Advisors, the compensation for Board service (RSUs and Share Options) is directed to the Funds, meaning Felix J. Baker, Dr. Biggar, and M. Cantey Boyd do not have a direct right to these specific securities.
• Baker Bros. Advisors LP, serving as the investment adviser to the Funds, maintains complete discretion and authority over the investment and voting power of the securities held by the Funds.
• The filing also notes that Felix J. Baker and Julian C. Baker directly hold 14,840 Class A Ordinary Shares each.

Sentiment

Score: 7

Explanation: The filing reports routine equity grants to directors, which is generally positive for aligning management interests with shareholders. There are no negative financial implications or risks explicitly reported. The grants are part of a standard incentive plan, indicating stability and long-term commitment from key stakeholders.

Positives

• The granting of RSUs and Share Options to key directors and affiliates fosters a strong alignment of their interests with the long-term performance and shareholder value of Kiniksa Pharmaceuticals.
• The structured vesting schedules for both RSUs (by June 3, 2026) and Share Options (12 monthly installments from July 3, 2025) incentivize continued service and commitment from the board members.
• The options' strike price of $29.11 provides a clear performance incentive, requiring the stock price to appreciate for the options to be profitable, which benefits all shareholders.

Negatives

• No explicit negative points or adverse financial implications are detailed in this Form 4 filing, which primarily reports routine equity grants.

Risks

• No specific risks are mentioned or highlighted within this Form 4 filing.

Future Outlook

The equity awards are structured with future vesting conditions and an option expiration date in 2035, indicating an expectation of long-term engagement from the directors and a strategic focus on future shareholder value creation through the company's established 2018 Incentive Award Plan.

Management Comments

• "Felix J. Baker, a managing member of Baker Bros. Advisors (GP) LLC and Dr. Biggar, and M. Cantey Boyd full-time employee of Baker Bros. Advisors LP, are directors of Kiniksa Pharmaceuticals International, plc."
• "By virtue of their representation on the board of directors of the Issuer, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, the reporting persons other than Felix J. Baker are deemed directors by deputization of the Issuer."
• "Pursuant to the policies of the Adviser, Felix J. Baker, Dr. Biggar and M. Cantey Boyd do not have a right to any of the Issuer's securities issued as compensation for their service on the Board and the Funds are entitled to an indirect proportionate pecuniary interest in such securities."
• "Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by or held for the benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."

Industry Context

This Form 4 filing reflects a common practice within the biotechnology and pharmaceutical industries, where equity compensation, including RSUs and stock options, is widely utilized to attract, retain, and incentivize key executives and directors. Such grants are crucial for aligning management and board interests with the long-term performance of the company, particularly in a sector characterized by extensive research and development cycles and significant capital investment.

Comparison to Industry Standards

• The use of Restricted Share Units (RSUs) and Non-Qualified Share Options for director compensation is a standard practice across the biotechnology and pharmaceutical industries, comparable to compensation structures observed in major players like Biogen Inc. (BIIB) or Gilead Sciences, Inc. (GILD).
• The vesting schedule for RSUs (vesting by June 2026 or next annual meeting) and options (12 monthly installments) is typical for aligning director incentives with sustained company performance, mirroring plans seen at peer companies.
• The specified strike price of $29.11 for the options indicates a performance-based incentive, requiring stock price appreciation for the options to become valuable, which is a standard feature of equity incentive plans designed to motivate value creation.

Management Changes

Corporate Governance

Legal Proceedings

• No legal proceedings or regulatory matters are mentioned in this Form 4 filing.

Related Party Transactions

• The equity grants to Felix J. Baker, Dr. Stephen R. Biggar, and M. Cantey Boyd, who serve as directors and are employees/managing members of Baker Bros. Advisors LP and its affiliates (the reporting persons), constitute related party transactions.
• The structure of indirect pecuniary interest through the Funds (667, L.P. and Baker Brothers Life Sciences, L.P.) and the disclaimer of direct beneficial ownership by Julian C. Baker, Felix J. Baker, Baker Bros. Advisors (GP) LLC, and Baker Bros. Advisors LP, highlights the complex related party relationships and their management of these interests.

Stakeholder Impact

• **Shareholders**: The equity grants align the interests of key directors and significant shareholders (Baker Bros. Advisors and its Funds) with the long-term performance of the company, potentially leading to increased shareholder value if the stock price appreciates.
• **Employees**: While the grants are specifically for directors, they are part of an overall incentive plan, which can signal a broader commitment to performance-based compensation within the company, potentially influencing employee morale and retention.

Next Steps

• The Restricted Share Units (RSUs) are expected to fully vest on the earlier of June 3, 2026, or the date of the next annual meeting of shareholders.
• The Non-Qualified Share Options will begin vesting in 12 equal monthly installments starting on July 3, 2025.

Key Dates

Recommendation

Keywords

Kiniksa Pharmaceuticals, KNSA, SEC Form 4, Equity Grants, Restricted Share Units, RSUs, Share Options, Stock Options, Director Compensation, Beneficial Ownership, Baker Bros. Advisors, Biotechnology, Pharmaceuticals, Insider Transaction